BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 16315314)

  • 1. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
    Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients.
    Munoz-Price LS; Slifkin M; Ruthazer R; Poutsiaka DD; Hadley S; Freeman R; Rohrer R; Angelis M; Cooper J; Fairchild R; Barefoot L; Bloom J; Fitzmaurice S; Snydman DR
    Clin Infect Dis; 2004 Nov; 39(9):1293-9. PubMed ID: 15494905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
    Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
    Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
    Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
    Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
    Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
    Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.
    Seehofer D; Rayes N; Neumann UP; Meisel H; Oettle H; Nüssler NC; Jonas S; Langrehr JM; Neuhaus P
    Transpl Int; 2005 Aug; 18(8):941-8. PubMed ID: 16008744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
    Tryphonopoulos P; Weppler D; Morris MI; Russo C; Nishida S; Levi DM; Moon J; Tekin A; Selvaggi G; Island E; Arosemena L; Ruiz P; Tzakis AG
    Transplantation; 2011 Nov; 92(9):1051-7. PubMed ID: 21876474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N; Wannstedt C; Keyes L; Wagener MM; Cacciarelli TV
    Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.
    Seehofer D; Rayes N; Tullius SG; Schmidt CA; Neumann UP; Radke C; Settmacher U; Müller AR; Steinmüller T; Neuhaus P
    Liver Transpl; 2002 Dec; 8(12):1138-46. PubMed ID: 12474153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
    McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
    Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after ganciclovir treatment.
    Loginov R; Höckerstedt K; Lautenschlager I
    Arch Virol; 2003 Jul; 148(7):1269-74. PubMed ID: 12827460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen.
    Krampe K; Briem-Richter A; Fischer L; Nashan B; Ganschow R
    Pediatr Transplant; 2010 Feb; 14(1):67-71. PubMed ID: 19175517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.